Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 12 records, 2 pages
Search For: Erythropoietin Drugs
Global Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
02 Jan 2024
Pharma & Healthcare
According to our (Global Info Research) latest study, the global Erythropoietin Drugs market size was valued at USD 9422.9 million in 2023 and is forecast to a readjusted size of USD 13240 million by 2030 with a CAGR of 5.0% during review period.
USD3480.00
Add To Cart
Global Recombinant Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
02 Jan 2024
Pharma & Healthcare
Recombinant Erythropoietin Drugs
According to our (Global Info Research) latest study, the global Recombinant Erythropoietin Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Global Long-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2024-2030
06 Mar 2024
Pharma & Healthcare
Long-acting Recombinant Human Erythropoietin Drugs
The global Long-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 1142.9 million by 2030, rising at a market growth of 4.0% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
Global Long-acting Recombinant Human Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
19 Jan 2024
Pharma & Healthcare
Long-acting Recombinant Human Erythropoietin Drugs
According to our (Global Info Research) latest study, the global Long-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 867.4 million in 2023 and is forecast to a readjusted size of USD 1142.9 million by 2030 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2024-2030
06 Mar 2024
Pharma & Healthcare
Short-acting Recombinant Human Erythropoietin Drugs
The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
Global Short-acting Recombinant Human Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
19 Jan 2024
Pharma & Healthcare
Short-acting Recombinant Human Erythropoietin Drugs
According to our (Global Info Research) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 9433.4 million in 2023 and is forecast to a readjusted size of USD 14300 million by 2030 with a CAGR of 6.1% during review period.
USD3480.00
Add To Cart
Global Recombinant Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029
08 Feb 2023
Pharma & Healthcare
Recombinant Erythropoietin Drugs
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
USD4480.00
Add To Cart
Global Recombinant Erythropoietin Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
05 Jan 2023
Pharma & Healthcare
Recombinant Erythropoietin Drugs
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
USD3480.00
Add To Cart
Global Long-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029
25 Oct 2023
Pharma & Healthcare
Long-acting Recombinant Human Erythropoietin Drugs
The global Long-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 1142.9 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
Global Long-acting Recombinant Human Erythropoietin Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
25 Oct 2023
Pharma & Healthcare
Long-acting Recombinant Human Erythropoietin Drugs
According to our (Global Info Research) latest study, the global Long-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 867.4 million in 2022 and is forecast to a readjusted size of USD 1142.9 million by 2029 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
- 1
- 2
Go To Page
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: Erythropoietin Drugs
Total: 12 records, 2 pages
According to our (Global Info Research) latest study, the global Erythropoietin Drugs market size was valued at USD 9422.9 million in 2023 and is forecast to a readjusted size of USD 13240 million by 2030 with a CAGR of 5.0% during review period.
USD3480.00
Add To Cart
According to our (Global Info Research) latest study, the global Recombinant Erythropoietin Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
The global Long-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 1142.9 million by 2030, rising at a market growth of 4.0% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
According to our (Global Info Research) latest study, the global Long-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 867.4 million in 2023 and is forecast to a readjusted size of USD 1142.9 million by 2030 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period (2024-2030).
USD4480.00
Add To Cart
According to our (Global Info Research) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 9433.4 million in 2023 and is forecast to a readjusted size of USD 14300 million by 2030 with a CAGR of 6.1% during review period.
USD3480.00
Add To Cart
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
USD4480.00
Add To Cart
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
USD3480.00
Add To Cart
The global Long-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 1142.9 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
According to our (Global Info Research) latest study, the global Long-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 867.4 million in 2022 and is forecast to a readjusted size of USD 1142.9 million by 2029 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
- 1
- 2
Go To Page
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>